Placebo (ziltivekimab), ziltivekimab
EX6018-4758
Phase 3 small_molecule active
Quick answer
Placebo (ziltivekimab), ziltivekimab for Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active